VENTURE-Oral dosing
57 evidence topics · 12 sources
Objective
Registry statement of the study aims
Purpose of the exploratory maintenance cohort
Location and study date
Registry study dates
| Milestone | Registry entry |
|---|---|
| Study start (actual) | “2024-12-18” |
| Primary completion (actual) | “2025-06-24” |
| Study completion (actual) | “2025-08-15” |
| First posted | “2025-02-14” |
| Last update posted | “2025-10-06” |
Study sites in the United States
| Site | City | State |
|---|---|---|
| Site 111 | “Peoria” | “Arizona” |
| Site 105 | “Lake Forest” | “California” |
| Site 101 | “Clearwater” | “Florida” |
| Site 108 | “Largo” | “Florida” |
| Site 107 | “Ocoee” | “Florida” |
| Site 102 | “Port Orange” | “Florida” |
| Site 100 | “Indianapolis” | “Indiana” |
| Site 110 | “Louisville” | “Kentucky” |
| Site 114 | “Marrero” | “Louisiana” |
| Site 109 | “City of Saint Peters” | “Missouri” |
| Site 112 | “Kansas City” | “Missouri” |
| Site 113 | “Butte” | “Montana” |
| Site 103 | “Knoxville” | “Tennessee” |
| Site 104 | “Austin” | “Texas” |
| Site 106 | “San Antonio” | “Texas” |
Congress presentation of the results
Study design
Randomized, double-blind, placebo-controlled multicenter design
Registry design and masking
| Design element | Registry entry |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
| Primary purpose | “Treatment” |
Seven-arm randomization with screening and follow-up periods
Phase designation in company documents
Eligibility criteria
Inclusion criteria
Body mass index requirement in company documents
Treatment
Once-daily oral tablet dose arms and titration schedules
Exploratory maintenance cohort: 90 mg induction followed by 30 mg daily
Titration in two-week steps starting at 30 mg
Tablet strength, pill count, and fasting administration
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint: percent change in body weight at week 13
Secondary endpoints: proportions reaching 5% and 10% weight loss
Safety outcomes
Pharmacokinetic outcomes not reported
Clinical relevance of weight reduction cited by the investigators
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm
Description of analysis sets
Efficacy and safety populations
Modified intention-to-treat population in the poster
Statistical models for the primary and key secondary endpoints
Sample size calculation and multiplicity control
No evidence found.
Estimand and handling of missing data
No evidence found.
Results
Participant disposition
Treatment and study discontinuation by dose
| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Discontinued treatment early, n (%) | “7 (18)” | “8 (20)” | “8 (20)” | “11 (28)” | “10 (25)” | “15 (38)” |
| TEAE leading to treatment discontinuation, n (%) | “5 (13)” | “2 (5)” | “5 (13)” | “7 (18)” | “8 (20)” | “12 (30)” |
| Drug-related TEAE leading to treatment discontinuation, n (%) | “3 (8)” | “1 (3)” | “5 (13)” | “6 (15)” | “8 (20)” | “11 (28)” |
| Discontinued study early, n (%) | “2 (5)” | “4 (10)” | “5 (13)” | “5 (13)” | “3 (8)” | “5 (13)” |
| TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
| Drug-related TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
Pooled discontinuation rates, VK2735 versus placebo
Distinction between treatment discontinuation and study discontinuation
Reasons for discontinuation
Exploratory maintenance cohort discontinuation
Baseline characteristics
Baseline characteristics by arm, safety population
| Characteristic | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Age, mean years | “51” | “54” | “53” | “49” | “52” | “50” |
| Sex, % male:female | “30:70” | “20:80” | “45:55” | “15:85” | “32:68” | “28:72” |
| White, % | “85” | “80” | “73” | “68” | “88” | “83” |
| Non-Hispanic, % | “70” | “78” | “80” | “85” | “75” | “73” |
| Weight, mean kg | “105” | “99” | “103” | “103” | “103” | “102” |
| BMI, mean kg/m2 | “38” | “37” | “35” | “37” | “37” | “37” |
| Prediabetes, % | “53” | “45” | “60” | “38” | “68” | “63” |
Overall population: age, sex, race, and prediabetes definition
Mean baseline body weight by arm, efficacy population
| Arm | Mean baseline body weight |
|---|---|
| Placebo | “105.2 kg” |
| VK2735 15 mg | “99.0 kg” |
| VK2735 30 mg | “102.9 kg” |
| VK2735 60 mg | “102.8 kg” |
| VK2735 90 mg | “103.4 kg” |
| VK2735 120 mg | “101.9 kg” |
| Exploratory maintenance cohort | “102.8 kg” |
Efficacy results
Primary and key secondary endpoints at week 13 by dose
| Measure | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants, efficacy population | “(n=40)” | “(n=40)” | “(n=40)” | “(n=38)” | “(n=39)” | “(n=39)” |
| Mean change from baseline body weight, least squares mean | “-1.3 kg” | “-2.2 kg” | “-7.1 kg” | “-8.8 kg” | “-11.5 kg” | “-12.1 kg” |
| Mean percent change from baseline, least squares mean | “-1.3 %” | “-2.3 %” | “-7.0 %” | “-8.7 %” | “-11.1 %” | “-12.2 %” |
| p-value versus baseline | “-” | “0.0057” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Placebo-adjusted mean percent change from baseline | “-” | “-1.0 %” | “-5.7 %” | “-7.4 %” | “-9.8 %” | “-10.9 %” |
| p-value versus placebo, percent change | “-” | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Percent reporting at least 10% weight loss | “5 %” | “8 %” | “35 %” | “40 %” | “59 %” | “80 %” |
| p-value versus placebo, at least 10% weight loss | “-” | “-” | “<0.01” | “0.0017” | “< 0.0001” | “<0.0001” |
Proportions achieving at least 5% and at least 10% weight loss
Time course of weight loss from week 1 through week 13
Exploratory maintenance cohort: weight change after transition from 90 mg to 30 mg
| Measure | Week 3, 90 mg | Week 6, 90 mg | Week 9, 30 mg | Week 13, 30 mg |
|---|---|---|---|---|
| Mean change from baseline body weight, least squares mean | “-5.2 kg” | “-8.1 kg” | “-8.8 kg” | “-9.1kg” |
| Mean percent change from baseline, least squares mean | “-5.1 %” | “-8.1 %” | “-8.8 %” | “-9.2 %” |
| Placebo-adjusted mean percent change from baseline | “-4.3 %” | “-6.7 %” | “-7.6 %” | “-7.9 %” |
| p-value versus placebo | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
Weight change at week 16, three weeks after the last dose
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by dose
Severity of adverse events
Pooled nausea and vomiting rates, VK2735 versus placebo
Common drug-related gastrointestinal adverse events by dose
| Event, number of participants reporting (%) | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Gastroesophageal reflux disease | “0 (0%)” | “3 (8%)” | “0 (0%)” | “2 (5%)” | “1 (3%)” | “3 (8%)” |
| Nausea, mild | “16 (40%)” | “12 (30%)” | “15 (38%)” | “13 (33%)” | “22 (55%)” | “15 (38%)” |
| Nausea, moderate | “3 (8%)” | “2 (5%)” | “7 (18%)” | “8 (20%)” | “7 (18%)” | “7 (18%)” |
| Nausea, severe | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “2 (5%)” |
| Vomiting | “4 (10%)” | “2 (5%)” | “6 (15%)” | “8 (20%)” | “14 (35%)” | “14 (35%)” |
| Abdominal pain | “1 (3%)” | “1 (3%)” | “2 (5%)” | “1 (3%)” | “1 (3%)” | “2 (5%)” |
| Diarrhea | “5 (13%)” | “2 (5%)” | “3 (8%)” | “6 (15%)” | “6 (15%)” | “10 (25%)” |
| Constipation | “9 (23%)” | “9 (23%)” | “8 (20%)” | “12 (30%)” | “17 (43%)” | “11 (28%)” |
Drug-related gastrointestinal adverse events by severity grade
| Severity | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Any drug-related GI TEAE, mild, grade 1, n (%) | “17 (43)” | “18 (45)” | “16 (40)” | “18 (45)” | “21 (53)” | “18 (45)” |
| Any drug-related GI TEAE, moderate, grade 2, n (%) | “6 (15)” | “6 (15)” | “11 (28)” | “12 (30)” | “13 (33)” | “11 (28)” |
| Any drug-related GI TEAE, severe, grade 3, n (%) | “1 (3)” | “0” | “0” | “0” | “0” | “2 (5)” |
| Nausea, mild/moderate/severe, % of participants | “40/8/0” | “30/5/0” | “38/18/0” | “33/20/0” | “55/18/0” | “38/18/5” |
| Constipation, mild/moderate/severe, % of participants | “13/10/0” | “13/10/0” | “10/10/0” | “20/10/0” | “33/10/0” | “25/3/0” |
| Vomiting, mild/moderate/severe, % of participants | “3/8/0” | “5/0/0” | “8/8/0” | “18/3/0” | “30/5/0” | “15/15/5” |
| Diarrhea, mild/moderate/severe, % of participants | “10/0/3” | “5/0/0” | “8/0/0” | “15/0/0” | “10/5/0” | “15/10/0” |
Time course of gastrointestinal adverse events
Placebo adverse event rates and the company's interpretation
Titration rate and gastrointestinal tolerability
Exploratory maintenance cohort adverse events
Laboratory values, vital signs, and heart rate
No evidence found.
Study limitations
Summary: limitations of the VENTURE-Oral Dosing evidence
Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.
Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.
Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.
The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.
The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.